Abstract: To select a shoulder-tap method or a set of methods that optimizes the delivery of a shoulder-tap with respect to feasibility, reliability, and cost, in accordance with the present invention. Each shoulder-tap method can be evaluated on its feasibility, reliability and cost. A shoulder-tap method can be selected and used that optimizes reliability and cost with respect to feasibility constraints.
Type:
Application
Filed:
February 22, 2012
Publication date:
August 22, 2013
Applicant:
AERIS COMMUNICATIONS
Inventors:
Kirk E. BREZEE, Byung Hoon SIM, Dae Seong KIM, Syed Z. HOSAIN, Lotus WEYGANDT, Saraswathi BALASUBRAMANIAM, Michael GARNER
Abstract: The present invention a method for assigning a temporary dialable number to a device having a non-dialable number so that the device may have the capability to be connected with, such as in being called back. In addition to the numerous benefits provides by the present invention, mobile device user in particular, are provided benefits to enable the health, safety and security of individuals who utilize emergency-based systems that do not have a dialable mobile device number (MDN) by the present invention.
Type:
Application
Filed:
March 19, 2012
Publication date:
April 25, 2013
Applicant:
AERIS COMMUNICATIONS, INC.
Inventors:
Yixiang CHEN, Drew S. JOHNSON, Syed Zaeem HOSAIN, Mark E. CRATSENBURG, Kirk E. BREZEE, Dae Seong KIM
Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.
Type:
Application
Filed:
June 11, 2012
Publication date:
September 27, 2012
Applicant:
AERIS THERAPEUTICS, INC.
Inventors:
Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
Abstract: A system and method for enabling a service provider to select one or more digital cellular markets to receive a broadcast page, wherein each digital cellular market provides wireless communication services to a geographic region. The service provider to generate a broadcast page indicating a Virtual Device Identifier, the Virtual Device Identifier associated with a plurality of remote devices in each of the digital cellular markets selected, and wherein each of the remote devices includes a Primary Device Identifier uniquely identifying the remote device within the digital cellular markets, and wherein each of the remote devices further includes the Virtual Device Identifier associated with the plurality of remote devices. The service provider to further send the broadcast page to each digital cellular market selected, for transmission to the remote devices to send a message to remote devices having the Virtual Device Identifier.
Type:
Application
Filed:
March 20, 2009
Publication date:
September 24, 2009
Applicant:
AERIS COMMUNICATIONS, INC.
Inventors:
Byung Hoon Sim, Syed Zaeem Hosain, Robert B. Fultz, Dae Seong Kim
Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.
Type:
Application
Filed:
May 8, 2008
Publication date:
November 13, 2008
Applicant:
AERIS THERAPEUTICS, INC.
Inventors:
Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
Abstract: One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels.
Abstract: One aspect of the present invention relates to compositions and methods comprising polyelectrolyte molecules for treating patients who have certain diseases. Aspects of the invention relate to using certain polyelectrolyte compositions in therapy. According to the invention polyelectrolyte compositions may be used, for example, to slow or stop cell growth, kill cells (e.g., via necrotic or apoptotic pathways), promote fibrosis, or a combination thereof. In one aspect of the invention, certain toxic (e.g., cytotoxic) properties of polyelectrolytes are exploited for therapeutic purposes. In certain embodiments, compositions and methods of the invention are used to target polyelectrolyte toxicity to predetermined regions within a subject, while minimizing undesirable toxicity at other regions with the subject. In certain embodiments, the present invention relates to lung-volume-reduction therapy using a polyelectrolyte composition.
Type:
Application
Filed:
October 31, 2006
Publication date:
May 17, 2007
Applicant:
AERIS THERAPEUTICS, INC.
Inventors:
Edward Ingenito, Alexander Schwarz, Larry Tsai